Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Teva's Shrinking U.S. Footprint February 22, 2018 Veracyte Announces Anthem Coverage For The Afirma Gene Expression Classifier For Use In Thyroid Cancer Diagnosis May 18, 2017 Booming Bay Area Biotechs' Huge Headache: Where to House Their Employees October 12, 2017
Veracyte Announces Anthem Coverage For The Afirma Gene Expression Classifier For Use In Thyroid Cancer Diagnosis May 18, 2017
